The efficacy and safety of anamorelin among patients with diabetes.
Anamorelin
Cancer cachexia
Diabetes
Hyperglycaemia
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
received:
11
01
2024
accepted:
30
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
Anamorelin is a selective ghrelin receptor agonist approved for cancer cachexia in Japan. Little is known about predictors of anamorelin efficacy. This study aimed to assess the effect of diabetes on the efficacy and safety of anamorelin in patients with cancer cachexia. Medical records of patients with advanced non-small-cell lung, gastric, pancreatic, or colorectal cancer who received anamorelin between January 2021 and March 2023 were retrospectively reviewed. The diabetic (DM) group included patients with a confirmed diagnosis of type 2 diabetes mellitus, random plasma glucose of ≥ 200 mg/dL, or hemoglobin A1c of ≥ 6.5%. The maximum body weight gain and adverse events during anamorelin administration were compared between the DM and non-DM groups. Patients with a maximum body weight gain ≥ 0 kg were classified as the responders. Of 103 eligible patients, 31 (30.1%) were assigned to the DM group. The DM group gained less weight (median of -0.53% vs. + 3.00%, p < 0.01) and had fewer responders (45.2% vs. 81.9%, p < 0.01) than the non-DM group. The odds ratio for non-response in the DM group was 6.55 (95% confidential interval 2.37-18.06, p < 0.01), adjusted by age and performance status. The DM group had a higher cumulative incidence of hyperglycaemic adverse events (72.2% vs. 6.3%, p < 0.01) and more discontinuations due to hyperglycaemic adverse events (25.8% vs. 4.2%, p < 0.01) than the non-DM group. Patients with diabetes and cancer cachexia are less likely to gain weight with anamorelin despite a high risk of hyperglycaemic adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Anamorelin is a selective ghrelin receptor agonist approved for cancer cachexia in Japan. Little is known about predictors of anamorelin efficacy. This study aimed to assess the effect of diabetes on the efficacy and safety of anamorelin in patients with cancer cachexia.
METHODS
METHODS
Medical records of patients with advanced non-small-cell lung, gastric, pancreatic, or colorectal cancer who received anamorelin between January 2021 and March 2023 were retrospectively reviewed. The diabetic (DM) group included patients with a confirmed diagnosis of type 2 diabetes mellitus, random plasma glucose of ≥ 200 mg/dL, or hemoglobin A1c of ≥ 6.5%. The maximum body weight gain and adverse events during anamorelin administration were compared between the DM and non-DM groups. Patients with a maximum body weight gain ≥ 0 kg were classified as the responders.
RESULTS
RESULTS
Of 103 eligible patients, 31 (30.1%) were assigned to the DM group. The DM group gained less weight (median of -0.53% vs. + 3.00%, p < 0.01) and had fewer responders (45.2% vs. 81.9%, p < 0.01) than the non-DM group. The odds ratio for non-response in the DM group was 6.55 (95% confidential interval 2.37-18.06, p < 0.01), adjusted by age and performance status. The DM group had a higher cumulative incidence of hyperglycaemic adverse events (72.2% vs. 6.3%, p < 0.01) and more discontinuations due to hyperglycaemic adverse events (25.8% vs. 4.2%, p < 0.01) than the non-DM group.
CONCLUSIONS
CONCLUSIONS
Patients with diabetes and cancer cachexia are less likely to gain weight with anamorelin despite a high risk of hyperglycaemic adverse events.
Identifiants
pubmed: 38722487
doi: 10.1007/s10147-024-02546-8
pii: 10.1007/s10147-024-02546-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495
doi: 10.1016/S1470-2045(10)70218-7
Temel JS, Abernethy AP, Currow DC et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519–531
doi: 10.1016/S1470-2045(15)00558-6
Katakami N, Uchino J, Yokoyama T et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124:606–616
doi: 10.1002/cncr.31128
Hamauchi S, Furuse J, Takano T et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125:4294–4302
doi: 10.1002/cncr.32406
Iwai N, Sakai H, Oka K et al (2023) Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer 31:115
doi: 10.1007/s00520-023-07576-y
Takeda T, Sasaki T, Okamoto T et al (2023) Impact of the extent of weight loss before administration on the efficacy of anamorelin in advanced pancreatic cancer patients with cachexia. Intern Med 62:1887–1893
doi: 10.2169/internalmedicine.0730-22
Dev R, Bruera E, Dalal S (2018) Insulin resistance and body composition in cancer patients. Ann Oncol 29(Suppl 2):ii18–ii26
doi: 10.1093/annonc/mdx815
Tsilidis KK, Kasimis JC, Lopez DS et al (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607
doi: 10.1136/bmj.g7607
Hirata Y, Nomura K, Senga Y et al (2019) Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. Insight 4:e124952
Chovsepian A, Prokopchuk O, Petrova G et al (2023) Diabetes increases mortality in patients with pancreatic and colorectal cancer by promoting cachexia and its associated inflammatory status. Mol Metab 73:101729
doi: 10.1016/j.molmet.2023.101729
pmcid: 10192649
ElSayed NA, Aleppo G, Aroda VR et al (2023) 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S19–S40
doi: 10.2337/dc23-S002
Takayama H, Takiguchi T, Komura N et al (2023) Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study. Cancer Med 12(3):2918–2928
doi: 10.1002/cam4.5206
Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19:267–273
doi: 10.1016/j.ghir.2008.12.003
Miyazaki M, Sawada A, Sawamura D et al (2023) Decreased insulin-like growth factor-1 expression in response to mechanical loading is associated with skeletal muscle anabolic resistance in cancer cachexia. Growth Horm IGF Res 69–70:101536
doi: 10.1016/j.ghir.2023.101536
Clemmons DR (2012) Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 41:425–443
doi: 10.1016/j.ecl.2012.04.017
pmcid: 3374394
Suda K, Matsumoto R, Fukuoka H et al (2016) The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients. Growth Horm IGF Res 29:4–10
doi: 10.1016/j.ghir.2016.03.002
Honors MA, Kinzig KP (2012) The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle 3:5–11
doi: 10.1007/s13539-011-0051-5
Martin A, Gallot YS, Freyssenet D (2023) Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. J Cachexia Sarcopenia Muscle 14:1150–1167
doi: 10.1002/jcsm.13073
pmcid: 10235899
Heppner KM, Tong J (2014) Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol 171:R21–R32
doi: 10.1530/EJE-14-0183
Ohta H, Horii T, Yasu T (2023) Adverse metabolic effects on glucose in patients receiving anamorelin using a japanese claims database. Oncology 101(12):782–785
doi: 10.1159/000533539